

RELATIONSHIP BETWEEN SERUM THYROID HORMONE AND INTERLEUKIN-1 β LEVELS AND POSTMORTEM TISSUE DEIODINASE ACTIVITY IN CRITICALLY ILL PATIENTS

ODNOS IZMEĐU NIVOVA SERUMSKOG TIROIDNOG HORMONA I INTERLEUKINA-1 β I AKTIVNOSTI DEJODINAZE POSTMOTREM TKIVA KOD PACIJENATA U KRITIČNOM STANJU

ZhenZhou Zhong, XiaoLiu Xiao

Department of Emergency, Ganzhou People's Hospital, Ganzhou City, JiangXi Province, 341000, China

Summary

Background: This study investigated the relationship between serum thyroid hormones and interleukin-1 β (IL-1 β) levels and postmortem tissue deiodinase activity in critically ill patients.

Methods: Serum thyroid hormones and IL-1 β were measured on the 5th, 15th, and last day of 80 critically ill patients. Forty of these patients were non-survived, and liver and skeletal muscle were harvested to analyze type 1, 2, and 3 iodothyronine deiodinases (D1, D2, and D3) activity.

Results: Serum thyroid stimulating hormone (TSH), tetraiodothyronine (T4), and triiodothyronine (T3) were decreased, and reverse triiodoth while serum TSH, T4, and T3 levels decreased or remained unchanged, and rT3 and IL-1 β increase yronine (rT3) and IL-1 β were increased in non-survivors. From day 5 to the last day, serum TSH, T4, and T3 levels increased, and rT3 and IL-1 β levels decreased with time in survivors, while serum TSH, T4, and T3 levels decreased or remained unchanged, and rT3 and IL-1 β increased in non-survivors. On the last day, liver D1 activity was negatively correlated with serum rT3 and IL-1 β , while liver and skeletal muscle D3 activities were positively correlated.

Conclusion: Serum thyroid hormones and IL-1 β are correlated with postmortem deiodinase activity in critically ill patients.

Keywords: critical illness, prognostic markers, thyroid hormone, IL-1 β , deiodinase

Kratak sadržaj

Uvod: Cilj ovog istraživanja je bio da ispita odnos između nivoa serumskih hormona štitne žlezde i interleukina-1 β (IL-1 β) i aktivnosti dejodinaze postmortem tkiva kod pacijenata u kritičnom stanju.

Metode: Nivoi serumskih hormona štitne žlezde i IL-1 β su mereni petog, petnaestog i poslednjeg dana kod 80 pacijenata u kritičnom stanju. Četrdeset od ovih pacijenata nije preživelo, a jetra i skeletni mišići su uzeti za analizu aktivnosti jodotironin dejodinaza tipa 1, 2 i 3 (D1, D2 i D3).

Rezultati: Nivoi serumskog hormona koji stimulise štitnu žlezdu (TSH), tetrajodotironina (T4) i trijodotironina (T3) su bili smanjeni, dok su reverzni trijodotironin (rT3) i IL-1 β bili povećani kod pacijenata koji nisu preživeli. Od petog do poslednjeg dana, nivoi serumskog TSH, T4 i T3 su se povećavali, a nivoi rT3 i IL-1 β su se vremenom smanjivali kod preživelih, dok su nivoi seruma TSH, T4 i T3 opadali ili ostajali nepromenjeni. S druge strane, rT3 i IL-1 β su se povećavali kod onih koji nisu preživeli. Poslednjeg dana, aktivnost jetrenog D1 je bila u negativnoj korelaciji sa serumskim rT3 i IL-1 β , dok su aktivnosti D3 jetre i skeletnih mišića bile u pozitivnoj korelaciji.

Zaključak: Nivoi serumskih hormona štitne žlezde i IL-1 β su povezani sa aktivnošću dejodinaze postmortem tkiva kod pacijenata u kritičnom stanju.

Ključne reči: kritična bolest, prognostički markeri, hormon štitne žlezde, IL-1 β , dejodinaza

Address for correspondence:

XiaoLiu Xiao
Department of Emergency, Ganzhou People's Hospital,
No.16, Meiguan Avenue, Zhonggong District, Ganzhou City,
JiangXi Province, 341000, China
e-mail: 13627074142@163.com

Introduction

Critical illness causes hormonal changes that differ between acute and long-term illnesses (1). In acute critical illness, serum catecholamines, growth hormone, and cortisol levels are elevated, insulin resistance is reduced, and low triiodothyronine (T3) syndrome is observed (2). In long-term critical illness, catecholamine and cortisol levels are reduced, and thyroid stimulating hormone (TSH) and thyroid hormone levels are reduced compared to acute cases. Although no evidence has indicated the harm of acute changes, it is unclear whether endocrine changes in long-term critical illness are all beneficial, as studies have shown that some changes may lead to clinical deterioration (3).

High-dose growth hormone, glucocorticoid, or thyroid hormone have no or even negative effects on clinical outcomes of critically ill patients (4–7). Intervening with the hypothalamic releasing factor may be possible to restore pulsating secretion of pituitary hormones and normalize peripheral hormone levels (8).

A decrease in serum T3 concentration in critical illness and an increase in serum reverse triiodothyronine (rT3) are associated with the severity of the disease (9). Type 1, 2, and 3 iodothyronine deiodinases (D1–3) mediate peripheral thyroid hormone metabolism. Specifically, D1 mediates the formation of serum T3 from tetraiodothyronine (T4) and metabolite rT3 breakdown D2 converts T4 to T3 through outer ring deiodination and is important for local T3 production, while D3 catalyzes the inactivation of T4 and T3, generating rT3 and 3,3'-T2 (10, 11). D1, D2, or both reduce the deiodination of peripheral T4, significantly reducing circulating T3 levels (12, 13). D1 is the main pathway of rT3 clearance, and this mechanism may explain the increase in serum rT3 levels (14). In addition to D1 activity reduction, impairment in transporting T4 and rT3 to D1-containing tissues may be another mechanism of thyroid hormone disorders (15). However, the possibility that increased D3 activity leads to decreased serum T3 levels and elevated rT3 levels should also be considered (16).

Critical illness has been shown to be associated with disturbed metabolic and inflammatory responses (17). Interleukin-1 β (IL-1 β) is a pro-inflammatory cytokine that is higher in non-survivors than in critically surviving patients (18). Other studies have shown that IL-1 β can cause damage or apoptosis of thyroid follicular cells and promote the onset of autoimmune thyroiditis (19–21). IL-1 β is involved in autoimmune thyroiditis by inducing intercellular adhesion molecule-1 on thyroid follicular cells and interfering with the integrity of thyroid epithelium (22, 23). More importantly, postoperative serum IL-1 β levels in critically ill patients after major abdominal surgery are associated with mortality (24). In addition, it has been shown that IL-1 β inhibits thyroid hormone receptor- β 1 gene expression (25), which inhibits hepatic D1

expression (26). Therefore, we chose IL-1 β as the focus of our study to investigate its relationship with prognosis and deiodinase activity in critically ill patients.

In short, the study observed serum thyroid hormones and IL-1 β in critically ill patients and analyzed the correlation between deiodinase activity with serum thyroid hormones and IL-1 β .

Materials and Methods

Patients

Eighty patients who were hospitalized for more than 5 days in an intensive care unit (ICU) were included in this analysis. Among them, there were 39 patients with cardiac surgery, 17 patients with complex surgery (defined as patients with complications after abdominopelvic surgery, lung or esophageal surgery, or vascular surgery), 9 patients with organ transplantation, 7 patients with trauma, burn, or prosthetic surgery, and 8 patients with other surgeries. Blood samples were taken on the 5th, 15th, and last day after admission to ICU. Forty patients did not survive, and liver and skeletal muscle (rectus abdominis) were obtained within minutes of death.

Serum analysis

Treatment of ICU patients often includes systemic or local infusions of heparin to prevent vascular coagulation, which largely affects the determination of serum-free thyroid hormones (27). Heparin can lead to falsely elevated free thyroid hormone results. Specifically, heparin can activate lipoprotein esterase *in vitro* to release free fatty acids, which can displace bound thyroid hormone from thyroxine-binding globulin, resulting in falsely elevated free thyroid hormone levels (27–29). Therefore, the determination of serum-free T4 and T3 was avoided. Vitros ECI Immunodiagnostic System (Ortho-Clinical Diagnostics) tested serum total T4, total T3, and TSH. rT3 was measured by radioimmunoassay (30). IL-1 β detected serum IL-1 β levels in an enzyme-linked immunosorbent assay kit (R&D Systems, USA). Normal TSH, T4, T3, and rT3 values in 80 healthy subjects were measured.

Peripheral blood mononuclear cells (PBMCs)

Whole blood (2 mL) was equally diluted with phosphate-buffered saline (PBS) and transferred into a centrifuge tube containing 3 mL Ficoll Paque (G.E. Healthcare). PBMCs were collected after centrifugation at 400 \times g for 20 min, rinsed twice in 10 mL PBS, and re-suspended in a lysis buffer for protein extraction.

Immunoblotting

PBMCs and loading buffer (Yeasen, Shanghai, China) were heated at 99 °C for 10 min. Protein was loaded onto the sodium dodecyl sulfate-polyacrylamide gel and then imprinted onto the polyvinylidene fluoride membrane. The membrane was incubated overnight with either IL-1 β (1:1000, R&D Systems) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:1000, Abcam) primary antibody at 4 °C and then with a secondary antibody. GAPDH was used as a loading control. The protein signaling was developed via Enhanced Chemiluminescence (Solarbio). Relative protein level was analyzed using QuantityOne v4.6 (Bio-Rad) and normalized to GAPDH.

Deiodinase activity

Homogenates were produced with human liver and skeletal muscle samples homogenized in PE buffers (0.1 mol/L phosphate, 2 mol/L ethylenediamine tetraacetic acid, pH 7.2) using Polytron (Kinematica AG, Lucerne, Switzerland), frozen, and stored at -80 °C. D1 activity in liver tissues was measured by incubating 10 μ g protein with 0.1 μ mol/L (3', 5'-¹²⁵I) rT3 (100,000 cpm) in 0.1 mL PED10 buffer (PE + 10 mmol/L dithiothreitol (DTT)) for 30 min. D2 activity in skeletal muscles was determined by incubating 200 μ g protein with 1 mmol/L (3', 5'-¹²⁵I) T4 (100,000 cpm) in 0.1 mL PED25 buffer (PE+25 mmol/L DTT) for 1 h. To prevent the labeled T4 substrate from being deiodized by the D3 inner ring, incubation was performed in 0.1 μ mol/L unlabeled T3. When 0.1 μ mol/L unlabeled T4 is present or absent, it is sufficient to saturate D2. D2 activity is equal to the deiodination of unlabeled T4 minus the deiodination of excess unlabeled T4. The procedure for further determination of ¹²⁵I yield is the same as the D1 determination above. D3 was detected by incubating 100 μ g liver protein or 200 μ g skeletal muscle protein with 1 mmol/L (3'-¹²⁵I) T3 (200,000 cpm) in 0.1 mL PED50 buffer (PE + 50 mmol/L DTT) for 1 h (31).

Statistical analysis

G*Power software (ver. 3.1.9.7; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany)

was used for efficacy analyses and sample size calculation (32). SPSS 22.0 was utilized for data analysis. Categorical variables were compared using Fisher's exact test and presented as frequencies. Continuous variables except age and body mass index (BMI) were analyzed using non-parametric tests. Continuous variables were expressed as mean \pm standard deviation or median (interquartile distance (IQR)). Differences between continuous variables were analyzed by t-test or Mann-Whitney U test, with the Spearman correlation coefficient used for correlation analysis. Serum thyroid hormone and IL-1 β levels in critically ill patients on the last day of the ICU were used as independent variables. Logistic regression analysis was performed to obtain the predictive probability values, and then the predictive value of serum thyroid hormone and IL-1 β levels in patient death was evaluated by receiver operating characteristic (ROC) curve analysis. P < 0.05 indicated a statistical difference.

Results

Baseline characteristics

No significant differences were observed in age, sex, BMI, and APACHE II score on the 5th day of the ICU between patients who survived and those who died, and patients who died had longer ICU stays (Table I).

Serum thyroid hormones and IL-1 β differ between survivors and non-survivors

Table II shows serum thyroid hormones and IL-1 β in surviving and non-survivors. Compared with the survivors, the serum TSH, T4, and T3 were decreased, and the serum rT3 and IL-1 β were increased in non-survivors. Moreover, from the 5th day to the last day, TSH, T4, and T3 increased with time, and rT3 and IL-1 β decreased in survivors, while TSH, T4, and T3 decreased or remained unchanged, and rT3 and IL-1 β increased in non-survivors. IL-1 β protein expression was increased in PBMCs of non-survivors on the last day compared with survivors (Figure 1A, B).

Table I Baseline characteristics of patients.

Parameters	Survivor	Non-Survivor	P
Age (yr)	61.2 \pm 15.6	61.7 \pm 15.2	0.885
Sex (male/female)	25/15	26/14	0.816
BMI (kg/m ²)	25.5 \pm 5.7	25.8 \pm 4.5	0.795
ICU stay (d)	16 (10–28)	11 (7–20)	0.003
APACHE II score on the fifth day of the ICU	11 (7–15)	12 (8–15)	0.702

Note: The Acute Physiology and Chronic Health Evaluation II (APACHE II) score reflects the severity of illness, with higher values indicating more severe illness.




Figure 1A-B Western blot detection of IL-1 β protein expression in peripheral blood mononuclear cells of critically ill patients on the last day of the ICU IL-1 β /GAPDH ratio, the relative expression level of IL-1 β protein was normalized to GAPDH.




Figure 2A-B Predictive value of serum thyroid hormones and IL-1 β on death in patients on the last day of the ICU.




Figure 3A-B Correlation between liver D1 and serum thyroid hormones and IL-1 β on the last day of the ICU.

Table II Serum thyroid hormones and IL-1 β levels in survivors and non-survivors.

Parameters	Day	Survivor	Non-Survivor	P
TSH (μ U/mL)	5	1.21 [0.48–2.26]	0.43 [0.12–1.34]	<0.001
	15	1.46 [0.68–2.45]	0.85 [0.26–2.39]	0.046
	Last day	1.48 [0.76–2.32]	0.45 [0.05–0.96]	<0.001
T4 (μ g/dL)	5	5.65 [4.08–7.21]	3.36 [2.47–5.28]	<0.001
	15	6.71 [4.91–8.23]	3.90 [2.88–6.93]	<0.001
	Last day	7.50 [6.11–8.79]	3.39 [2.01–5.45]	<0.001
T3 (ng/dL)	5	74.1 [59.2–92.3]	53.8 [42.1–70.6]	<0.001
	15	87.1 [66.3–107.8]	60.9 [50.5–77.1]	<0.001
	Last day	94.2 [78.0–109.6]	54.4 [42.1–70.0]	<0.001
rT3 (ng/dL)	5	41.0 [28.0–65.7]	59.2 [35.1–87.5]	<0.001
	15	37.5 [25.9–63.4]	63.7 [31.9–101.3]	<0.001
	Last day	33.6 [23.3–54.5]	91.0 [40.3–135.1]	<0.001
IL-1 (pg/mL)	5	6.35 [4.56–8.07]	9.18 [7.30–11.3]	0.001
	15	5.12 [4.05–6.74]	10.6 [8.14–12.5]	<0.001
	Last day	4.07 [3.23–5.48]	12.3 [10.5–13.6]	<0.001




Figure 4A-B Association of liver and skeletal muscle D3 with serum thyroid hormones and IL-1 β on the last day of the ICU.

Table III Correlation between tissue deiodinase activity and serum thyroid hormone and IL-1 on the last day of the ICU.

	Liver D1		Liver D3		Muscle D3	
	Spearman r	P	Spearman r	P	Spearman r	P
TSH (μ U/mL)	0.212	0.128	-0.235	0.116	-0.257	0.094
T4 (μ g/dL)	0.179	0.231	-0.176	0.243	-0.032	0.817
T3 (ng/dL)	0.144	0.332	-0.271	0.075	-0.154	0.309
rT3 (ng/dL)	-0.740	<0.001	0.400	0.011	0.415	0.008
IL-1 (pg/mL)	-0.707	<0.001	0.381	0.015	0.397	0.011

Predictive value of serum thyroid hormones and IL-1 β on the last day of the ICU on patient death

Serum thyroid hormones and IL-1 β levels of critically ill patients on the last day of the ICU were used as independent variables, and logistic regression analysis was performed to obtain the predictive probability values, and then the predictive value for the patients' deaths was evaluated by using ROC curve analysis. The results showed that serum rT3 and IL-1 β had high predictive value (Figure 2A, B).

Correlation of liver D1 with serum thyroid hormones and IL-1 β on the last day of the ICU

Spearman's correlation coefficient was used for correlation analysis. Postmortem liver D1 activity was negatively correlated with serum rT3 and IL-1 β on the last day of ICU (Figure 3A, B) but had no correlation with serum TSH, T4, or T3 levels (Table II).

Association of liver and skeletal muscle D3 with serum thyroid hormone and IL-1 β on the last day of the ICU

Postmortem D3 activities were positively associated with serum rT3 and IL-1 β levels on the last day of ICU (Figure 4A-D) but not with serum TSH, T4, or T3 levels (Table III).

Discussion

Patients suffering from critical illnesses who require treatment in the ICU uniformly present with alterations in circulating thyroid hormone levels that are referred to by several names such as »nonthyroidal illness syndrome,« »sick euthyroid syndrome,« or »low T3 syndrome« (33, 34). Decreased serum T3 and elevated rT3 are correlated with disease severity (9), and serum T4 is inversely correlated with mortality (35). This trial found that from day 5 to the last day of ICU, serum TSH, T4, and T3 increased and rT3 levels decreased with time in survivors, while serum TSH, T4, and T3 levels decreased or unchanged, and

serum rT3 levels increased in non-survivors. Serum rT3 on the last day indicated a correlation with post-mortem deiodinase activity.

Patients with significant changes in serum thyroid hormones have higher mortality (36, 37). This study found significant TSH, T4, and T3 differences between survivors and non-survivors. TSH, T4, and T3 were elevated in surviving patients but not non-surviving patients. From the 5th day to the last day, T4 and T3 continued to increase, and no further TSH was observed after the 15th day, indicating that T4 and T3 both increased with the initial increase of TSH. This is consistent with previous research showing elevated serum TSH leads to elevated T4, marking the beginning of disease recovery (38, 39). Throughout the ICU period, serum rT3 levels of non-survivors continued to rise. This may be due to the short half-life of rT3 (40, 41), which is a sensitive marker for acute changes in tissue decay-mediated thyroid hormone metabolism during death.

It is estimated that D1 in the liver and kidneys contributes 15–80% of peripheral T3, and D2-containing tissues contribute to the remaining extra-thyroid T3. D1 plays the greatest role in patients with hyperthyroidism, while D2 plays a significant role in patients with hypothyroidism. The decrease in D1 activity will lead to the decrease of T3 production by T4 and the decrease of rT3 clearance (10). Another possible mechanism for lowering and increasing serum T3 levels is that D1-expressing tissues have lower uptake of T4 and rT3 (14, 15). This study found that liver D1 activity was negatively correlated with serum rT3 levels.

Under normal conditions, D3 is only present in the liver of the developing fetus and protects the fetus from overexposure to thyroid hormone, indicating that pathological conditions in adulthood may be related to deiodinase changes, especially D3 (42, 43). D3 is expressed in human skeletal muscle (44). D3 may reduce skeletal muscle local thyroid hormone levels by converting T4 to rT3 and T3 to 3,3'-T2. D3 expression in hemangiomas may lead to low T4 and T3 and high rT3 levels (16). This study found that liver D3 activity positively correlated with serum rT3.

Notably, we were unable to detect any D2 in skeletal muscle samples from these patients, whereas D2 activity was present in skeletal muscle from normal subjects (45). Elevated serum rT3 concentration may lead to D2 inactivation in critically ill patients (46). D2 in skeletal muscle promotes the production of serum T3, especially in cases of hypothyroidism (47). Therefore, skeletal muscle D2 inactivation may also lead to decreased T3 levels in critically ill patients.

Critical illness is related to metabolic and inflammatory disorders (48). Postoperative serum IL-1 β levels are associated with mortality in critically ill patients after major abdominal surgery (49). In addition, it has been shown that IL-1 β inhibits thyroid hormone receptor- β 1 gene expression (50), which inhibits hepatic D1 expression (51). Therefore, we tested serum IL-1 β levels in critically ill patients and showed that serum IL-1 β levels were elevated in non-survivors compared with the survivors. From day 5 to the last day of ICU, serum IL-1 β of survivors decreased with time, while it increased in non-survivors. In addition, IL-1 β protein in PMBCs on the last day of non-survivors was increased compared with that of survivors. High levels of IL-1 β are associated with abnormal thyroid function (52). The relationship between deiodinase activity and serum IL-1 β was further analyzed. The results showed that liver D1 activity was negatively correlated with serum IL-1 β , while liver and skeletal muscle D3 activity was positively correlated with serum IL-1 β .

However, this study has some limitations. First, this study only explored the effect of one inflammatory factor, IL-1 β , on the prognosis of critically ill patients, and more inflammatory factors need to be included in the study. Second, the present study did not delve into the potential mechanisms by which IL-1 β affects deiodinase activity, and it is hoped that this can be further explored in the future.

Conclusion

This study is the first to explore the relationship between serum thyroid hormones and IL-1 β and tis-

sue deiodinase activity. Serum TSH, T4, and T3 levels were decreased compared with survivors, and rT3 and IL-1 β were increased in non-survivors. Liver D1 activity was negatively correlated with serum rT3 and IL-1 β , while liver and skeletal muscle D3 activities were positively correlated.

Acknowledgments. Not applicable.

Funding

Not applicable.

Availability of data and materials

The data are available from the corresponding author upon request.

Ethics statement

This study was approved by the Ganzhou People's Hospital ethics committee, and the guardian of every subject signed informed consent.

Authors' contributions

Z.Z. Zhong designed the research study. Z.Z. Zhong and X.L. Xiao performed the research. X.L. Xiao provided help and advice on the experiments. Z.Z. Zhong and X.L. Xiao analyzed the data.

Z.Z. Zhong wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.

References

1. Van den Berghe G. Dynamic neuroendocrine responses to critical illness. *Frontiers in Neuroendocrinology* 2002; 23(4): 370–91.
2. Ligtenberg J, Girbes A, Beentjes J, Tulleken J, van der Werf T, Zijlstra J. Hormones in the critically ill patient: to intervene or not to intervene? *Intensive Care Medicine* 2001; 27(10): 1567–77.
3. Van den Berghe G, Baxter R, Weekers F, Wouters P, Bowers C, Iranmanesh A, et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. *Clinical Endocrinology* 2002; 56(5): 655–69.
4. Takala J, Ruokonen E, Webster N, Nielsen M, Zandstra D, Vundelinckx G, et al. Increased mortality associated with growth hormone treatment in critically ill adults. *The New England Journal of Medicine* 1999; 341(11): 785–92.
5. Bone R, Fisher C, Clemmer T, Slotman G, Metz C, Balk R. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic

- shock. *The New England Journal of Medicine* 1987; 317(11): 653–8.
6. Slotman G, Fisher C, Bone R, Clemmer T, Metz C. Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. *The Methylprednisolone Severe Sepsis Study Group. Critical Care Medicine* 1993; 21(2): 191–5.
 7. Brent G, Hershman J. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. *The Journal of Clinical Endocrinology and Metabolism* 1986; 63(1): 1–8.
 8. Van den Berghe G. Growth hormone secretagogues in critical illness. *Hormone Research* 1999: 21–8.
 9. Docter R, Krenning E, de Jong M, Hennemann G. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. *Clinical Endocrinology* 1993; 39(5): 499–518.
 10. Bianco A, Salvatore D, Gereben B, Berry M, Larsen P. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. *Endocrine Reviews* 2002; 23(1): 38–89.
 11. Cicatiello A, Di Girolamo D, Dentice M. Metabolic Effects of the Intracellular Regulation of Thyroid Hormone: Old Players, New Concepts. *Frontiers in Endocrinology* 2018; 9: 474.
 12. Kaptein E, Robinson W, Grieb D, Nicoloff J. Peripheral serum thyroxine, triiodothyronine and reverse triiodothyronine kinetics in the low thyroxine state of acute nonthyroidal illnesses. A noncompartmental analysis. *The Journal of Clinical Investigation* 1982; 69(3): 526–35.
 13. Faber J, Thomsen H, Lumholtz I, Kirkegaard C, Siersbaek-Nielsen K, Friis T. Kinetic studies of thyroxine, 3,5,3'-triiodothyronine, 3,3,5'-triiodothyronine, 3',5'-diiodothyronine, 3,3'-diiodothyronine, and 3'-monoiodothyronine in patients with liver cirrhosis. *The Journal of Clinical Endocrinology and Metabolism* 1981; 53(5): 978–84.
 14. Kaptein E, Feinstein E, Nicoloff J, Massry S. Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. *The Journal of Clinical Endocrinology and Metabolism* 1983; 57(1): 181–9.
 15. Hennemann G, Docter R, Friesema E, de Jong M, Krenning E, Visser T. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. *Endocrine Reviews* 2001; 22(4): 451–76.
 16. Huang S, Tu H, Harney J, Venihaki M, Butte A, Kozakewich H, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. *The New England Journal of Medicine* 2000; 343(3): 185–9.
 17. Zaher S, Branco R, Meyer R, White D, Ridout J, Pathan N. Relationship between inflammation and metabolic regulation of energy expenditure by GLP-1 in critically ill children. *Clin Nutr* 2021; 40(2): 632–7.
 18. Yan Y, Jin P, Lu J, Cheng D, Xu J, Yuan J, et al. Postoperative cytokine levels and their predictive value in critical patients after major abdominal surgery: a retrospective cohort study. *Annals of Palliative Medicine* 2022; 11(1): 1–15.
 19. Guo Q, Wu Y, Hou Y, Liu Y, Liu T, Zhang H, et al. Cytokine Secretion and Pyroptosis of Thyroid Follicular Cells Mediated by Enhanced NLRP3, NLRP1, NLRC4, and AIM2 Inflammasomes Are Associated With Autoimmune Thyroiditis. *Frontiers in Immunology* 2018; 9: 1197.
 20. Zhang Q, Ye X, Zhou Z, Zhu C, Li R, Fang Y, et al. Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis. *Nature Communications* 2022; 13(1): 775.
 21. Cao Y, Sun Y, Jin X, Li X, Chen L, Qiu Y. TIM4/NLRP3 axis participates in the effects of M1 macrophages on inflammatory factor release, apoptosis and cell adhesion in thyroid follicular cells. *Experimental and Therapeutic Medicine* 2022; 24(5): 679.
 22. Zhao R, Zhou H, Su S. A critical role for interleukin-1 in the progression of autoimmune diseases. *International Immunopharmacology* 2013; 17(3): 658–69.
 23. Rebuffat S, Kammoun-Krichen M, Charfeddine I, Ayadi H, Bougacha-Elleuch N, Peraldi-Roux S. IL-1 and TSH disturb thyroid epithelium integrity in autoimmune thyroid diseases. *Immunobiology* 2013; 218(3): 285–91.
 24. Yan Y, Jin P, Lu J, Cheng D, Xu J, Yuan J, et al. Postoperative cytokine levels and their predictive value in critical patients after major abdominal surgery: a retrospective cohort study. *Ann Palliat Med* 2022; 11(1): 1–15.
 25. Kwakkel J, Wiersinga WM, Boelen A. Interleukin-1beta modulates endogenous thyroid hormone receptor alpha gene transcription in liver cells. *J Endocrinol* 2007; 194(2): 257–65.
 26. Kwakkel J, Wiersinga WM, Boelen A. Differential involvement of nuclear factor-kappaB and activator protein-1 pathways in the interleukin-1beta-mediated decrease of deiodinase type 1 and thyroid hormone receptor beta1 mRNA. *J Endocrinol* 2006; 189(1): 37–44.
 27. Mendel CM, Frost PH, Kunitake ST, Cavalieri RR. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. *J Clin Endocrinol Metab* 1987; 65(6): 1259–64.
 28. Haim A, Chanoine JP, Albersheim S, Mock T. Elevated free thyroxin levels following low molecular weight heparin treatment in a premature neonate. *Acta Paediatr* 2008; 97(12): 1601.
 29. Laji K, Rhidha B, John R, Lazarus J, Davies JS. Abnormal serum free thyroid hormone levels due to heparin administration. *QJM* 2001; 94(9): 471–3.
 30. Visser TJ, Docter R, Hennemann G. Radioimmunoassay of reverse tri-iodothyronine. *J Endocrinol* 1977; 73(2): 395–6.
 31. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. *J Clin Endocrinol Metab* 2003; 88(7): 3202–11.

32. Kang H. Sample size determination and power analysis using the G*Power software. *J Educ Eval Health Prof* 2021; 18: 17.
33. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. *Endocr Rev* 2011; 32(5): 670–93.
34. Boonen E, Van den Berghe G. Endocrine responses to critical illness: novel insights and therapeutic implications. *J Clin Endocrinol Metab* 2014; 99(5): 1569–82.
35. McIver B, Gorman C. Euthyroid sick syndrome: an overview. *Thyroid: official journal of the American Thyroid Association* 1997; 7(1): 125–32.
36. Kaptein E, Weiner J, Robinson W, Wheeler W, Nicoloff J. Relationship of altered thyroid hormone indices to survival in nonthyroidal illnesses. *Clinical Endocrinology* 1982; 16(6): 565–74.
37. Slag M, Morley J, Elson M, Crowson T, Nuttall F, Shafer R. Hypothyroxinemia in critically ill patients as a predictor of high mortality. *JAMA* 1981; 245(1): 43–5.
38. Hamblin P, Dyer S, Mohr V, Le Grand B, Lim C, Tuxen D, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. *The Journal of Clinical Endocrinology and Metabolism* 1986; 62(4): 717–22.
39. Bacci V, Schussler G, Kaplan T. The relationship between serum triiodothyronine and thyrotropin during systemic illness. *The Journal of Clinical Endocrinology and Metabolism* 1982; 54(6): 1229–35.
40. LoPresti J, Eigen A, Kaptein E, Anderson K, Spencer C, Nicoloff J. Alterations in 3,3',5'-triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine administration in man. *The Journal of Clinical Investigation* 1989; 84(5): 1650–6.
41. LoPresti J, Gray D, Nicoloff J. Influence of fasting and refeeding on 3,3',5'-triiodothyronine metabolism in man. *The Journal of Clinical Endocrinology and Metabolism* 1991; 72(1): 130–6.
42. Richard K, Hume R, Kaptein E, Sanders J, van Toor H, De Herder W, et al. Ontogeny of iodothyronine deiodinases in human liver. *The Journal of Clinical Endocrinology and Metabolism* 1998; 83(8): 2868–74.
43. Kester M, Kaptein E, Van Dijk C, Roest T, Tibboel D, Coughtrie M, et al. Characterization of iodothyronine sulfatase activities in human and rat liver and placenta. *Endocrinology* 2002; 143(3): 814–9.
44. Peeters R, Wouters P, Kaptein E, van Toor H, Visser T, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. *The Journal of Clinical Endocrinology and Metabolism* 2003; 88(7): 3202–11.
45. Salvatore D, Bartha T, Harney J, Larsen P. Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. *Endocrinology* 1996; 137(8): 3308–15.
46. Steinsapir J, Bianco A, Buettner C, Harney J, Larsen P. Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. *Endocrinology* 2000; 141(3): 1127–35.
47. Peeters R, van den Beld A, Attalki H, Toor H, de Rijke Y, Kuiper G, et al. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. *American Journal of Physiology Endocrinology and Metabolism* 2005; 289(1): E75–81.
48. Zaher S, Branco R, Meyer R, White D, Ridout J, Pathan N. Relationship between inflammation and metabolic regulation of energy expenditure by GLP-1 in critically ill children. *Clinical nutrition (Edinburgh, Scotland)* 2021; 40(2): 632–7.
49. Yan Y, Jin P, Lu J, Cheng D, Xu J, Yuan J, et al. Postoperative cytokine levels and their predictive value in critical patients after major abdominal surgery: a retrospective cohort study. *Ann Palliat Med* 2022; 11(1): 1–15.
50. Kwakkel J, Wiersinga WM, Boelen A. Interleukin-1beta modulates endogenous thyroid hormone receptor alpha gene transcription in liver cells. *J Endocrinol* 2007; 194(2): 257–65.
51. Kwakkel J, Wiersinga WM, Boelen A. Differential involvement of nuclear factor-kappaB and activator protein-1 pathways in the interleukin-1beta-mediated decrease of deiodinase type 1 and thyroid hormone receptor beta1 mRNA. *J Endocrinol* 2006; 189(1): 37–44.
52. Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. *Cancer Science* 2020; 111(5): 1468–77.

Received: January 16, 2024

Accepted: March 05, 2024